Comprehensive analysis of inhibitory checkpoint ligand expression by glioblastoma cells.

Immunology and Cell Biology
Laverne D RobilliardE Scott Graham

Abstract

Glioblastoma is a highly aggressive brain malignancy commonly refractory to classical and novel chemo-, radio- and immunotherapies, with median survival times of ~15 months following diagnosis. Poor immunological responses exemplified by the downregulation of T-cell activity, and upregulation of immunosuppressive cells within the tumor microenvironment have limited the effectiveness of immunotherapy in glioblastoma to date. Here we show that glioblastoma cells express a large repertoire of inhibitory checkpoint ligands known to control effector T cell responses. Furthermore, flow cytometry analysis reveals that glioblastoma cells with an enhanced stem cell-like phenotype express several investigated ligands at significant levels on their cell surface. This reveals that glioblastoma stem-like cells express suppressive ligands with the potential of suppressing major T cell checkpoint receptors. With this information, it is now essential that we understand the relevance of this extensive repertoire of immune checkpoint ligands and their functional consequence on immune evasion in glioblastoma. This is necessary to develop effective immunotherapeutics and to be able to match treatment to patient, especially in the light of CheckMat...Continue Reading

References

Jan 10, 2002·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Richard C AndersonJeffrey N Bruce
Nov 19, 2004·Nature·Sheila K SinghPeter B Dirks
Sep 18, 2009·Journal of Cellular Biochemistry·Candace A Gilbert, Alonzo H Ross
Jan 28, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tiziano Di TomasoCristina Maccalli
Nov 26, 2010·Cancer Research·Natalia Martin-OrozcoLaszlo Radvanyi
Jun 2, 2011·Cancer Research·Rudy BonaviaFrank B Furnari
Nov 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dieter LemkeWolfgang Wick
May 8, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ping MaoIchiro Nakano
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jun 26, 2015·Genes & Development·Justin D LathiaJeremy N Rich
Jul 25, 2015·Nature Reviews. Cancer·Ignacio MeleroJohn Haanen
Feb 18, 2016·Journal of Immunology Research·Eileen S KimMichael Lim
Jan 21, 2017·Clinical and Experimental Pharmacology & Physiology·Yanheng WuWenyi Gu
Apr 2, 2017·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Yael Diesendruck, Itai Benhar
Apr 15, 2017·Frontiers in Pharmacology·Talita GlaserXiang Zeng
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin
Dec 29, 2017·The Journal of Pathology·Daniel J Silver, Justin D Lathia
Feb 14, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karolina WoronieckaPeter E Fecci
Apr 10, 2018·Immunity·Vésteinn ThorssonIlya Shmulevich
May 13, 2018·Seminars in Cancer Biology·Dingxiao ZhangKiera Rycaj
Feb 23, 2019·Current Treatment Options in Oncology·Tresa McGranahanSeema Nagpal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.